Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density
Top Cited Papers
Open Access
- 30 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 25 (5) , 937-947
- https://doi.org/10.1359/jbmr.091035
Abstract
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone resorption in preclinical a...Keywords
This publication has 22 references indexed in Scilit:
- Drug-induced morphea: Report of a case induced by balicatib and review of the literatureJournal of the American Academy of Dermatology, 2008
- A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-InternationalInternational Journal Of Clinical Practice, 2008
- The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin KBioorganic & Medicinal Chemistry Letters, 2008
- Effect of Cathepsin K Inhibitor Basicity on in Vivo Off-Target ActivitiesMolecular Pharmacology, 2008
- Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?Journal of Bone and Mineral Research, 2007
- Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone TurnoverJournal of Bone and Mineral Research, 2005
- Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatmentStatistics in Medicine, 2005
- The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeuticsAdvanced Drug Delivery Reviews, 2005
- The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen DegradationJournal of Bone and Mineral Research, 2003
- Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone ResorptionJournal of Bone and Mineral Research, 2000